Nothing Special   »   [go: up one dir, main page]

Di Paolo et al., 2024 - Google Patents

Radionuclide-Conjugated Cancer-Specific Vectors: Peptides

Di Paolo et al., 2024

Document ID
17250290904061815899
Author
Di Paolo A
Marini I
Sarnelli A
Belli M
Paganelli G
Publication year
Publication venue
Radiotheranostics-A Primer for Medical Physicists I

External Links

Snippet

Targeted radionuclide therapy (ie the systemic administration of radionuclides or radiolabeled drugs directed against tumor-associated targets) is a nuclear medicine technique gaining increasing space in different clinical settings. Peptide receptor …
Continue reading at www.taylorfrancis.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Similar Documents

Publication Publication Date Title
Weiner et al. Radiolabeled peptides in oncology: role in diagnosis and treatment
Hicks et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin analogues
Chinol et al. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of Oncology Group
de Jong et al. Radiolabelled peptides for tumour therapy: current status and future directions: Plenary lecture at the EANM 2002
Kaltsas et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
Teunissen et al. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
Paganelli et al. Receptor-mediated radiotherapy with 90 Y-DOTA-D-Phe 1-Tyr 3-octreotide
Virgolini et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients
Pepe et al. Somatostatin receptor SPECT
Krebs et al. Comparison of 68 Ga-DOTA-JR11 PET/CT with dosimetric 177 Lu-satoreotide tetraxetan (177 Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Delpassand et al. Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide
Rodrigues et al. Comparison of 111 In-DOTA-D Phe 1-Tyr 3-octreotide and 111 In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours
Middendorp et al. Comparison of positron emission tomography with [^ sup 18^ F] FDG and [^ sup 68^ Ga] DOTATOC in recurrent differentiated thyroid cancer: preliminary data
Rambaldi et al. The present and future role of 111In pentetreotide in the PET era
Opalińska et al. NEN—the role of somatostatin receptor scintigraphy in clinical setting
Virgolini et al. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours
Salvatori et al. Radiobiology and radiation dosimetry in nuclear medicine
Di Paolo et al. Radionuclide-Conjugated Cancer-Specific Vectors: Peptides
Parisella et al. 99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma
Giovacchini et al. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors
Virgolini Mack Forster Award Lecture Receptor nuclear medicine: Vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients
Volterrani et al. Multiagent targeting of neuroendocrine neoplasms
Bal et al. Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors
Bodei et al. Diagnostic applications of nuclear medicine: Neuroendocrine tumors
Volterrani et al. Hybrid imaging and radionuclide therapy of neuroendocrine tumors